Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2018 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer

CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
November 13, 2018 07:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates

XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019 XMT-1522 Phase 1 Dose Escalation Enrollment Resumed Mersana to Present New Data on Dolasynthen and...
November 12, 2018 09:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer

CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
November 12, 2018 07:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018

Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage...
November 08, 2018 17:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
November 06, 2018 17:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates

CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
September 26, 2018 16:03 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
September 17, 2018 07:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522

CAMBRIDGE, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
August 08, 2018 16:03 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
August 08, 2018 16:01 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2018 Financial Results and Business Updates

CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...